Clinical Trial Update: Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor [Phase 2]

View source ↗

Summary

A Phase 2 randomized trial assessed fulvestrant with or without dasatinib in men and postmenopausal women with hormone receptor-positive advanced breast cancer …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Faslodex (fulvestrant)
• Sprycel (dasatinib)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Advanced Breast Cancer | Phase 2 | Status: COMPLETED | Results posted: 2016-05-25